Establishing induced pluripotent stem cell lines from two dominant optic atrophy patients with distinct OPA1 mutations and clinical pathologies

Frontiers in Genetics

Genetics

Alfredo A. Sadun¹  Jane W. Chan¹  Anh H. Pham¹  Xiangmei Zhang²  Katherine A. Pohl³  Xian-Jie Yang³ 

[1] Department of Ophthalmology, Doheny Eye Institute, University of California, Los Angeles, Pasadena, CA, United States;Department of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States;Department of Ophthalmology, Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, United States;Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, United States;

关键词: dominant optic atrophy;    DOA;    OPA1;    induced pluripotent stem cells (iPSC);    retinal ganglion cell;    RGC;   

DOI  :  10.3389/fgene.2023.1251216

 received in 2023-07-01, accepted in 2023-08-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

Dominant optic atrophy (DOA) is an inherited disease that leads to the loss of retinal ganglion cells (RGCs), the projection neurons that relay visual information from the retina to the brain through the optic nerve. The majority of DOA cases can be attributed to mutations in optic atrophy 1 (OPA1), a nuclear gene encoding a mitochondrial-targeted protein that plays important roles in maintaining mitochondrial structure, dynamics, and bioenergetics. Although OPA1 is ubiquitously expressed in all human tissues, RGCs appear to be the primary cell type affected by OPA1 mutations. DOA has not been extensively studied in human RGCs due to the general unavailability of retinal tissues. However, recent advances in stem cell biology have made it possible to produce human RGCs from pluripotent stem cells (PSCs). To aid in establishing DOA disease models based on human PSC-derived RGCs, we have generated iPSC lines from two DOA patients who carry distinct OPA1 mutations and present very different disease symptoms. Studies using these OPA1 mutant RGCs can be correlated with clinical features in the patients to provide insights into DOA disease mechanisms.

【 授权许可】

Unknown   
Copyright © 2023 Pohl, Zhang, Pham, Chan, Sadun and Yang.